Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Titel:
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Auteur:
Tannir, N.M. Albigès, L. McDermott, D.F. Burotto, M. Choueiri, T.K. Hammers, H.J. Barthélémy, P. Plimack, E.R. Porta, C. George, S. Donskov, F. Atkins, M.B. Gurney, H. Kollmannsberger, C.K. Grimm, M.-O. Barrios, C. Tomita, Y. Castellano, D. Grünwald, V. Rini, B.I. Jiang, R. Desilva, H. Fedorov, V. Lee, C.-W. Motzer, R.J.